文献速递肝病消化道出血消化内镜

预防食管静脉曲张再出血的风险分层:个体患者荟萃分析结果

Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis.
PubMed 文献 · Hepatology · 2017-08-26

该个体患者数据荟萃分析纳入比较内镜下曲张静脉套扎术联合β受体阻滞剂(EVL+BB)与单药治疗的随机对照试验,按Child A与B/C分层分析再出血和死亡。结果显示Child A患者联合治疗较单用BB减少再出血,Child B/C患者联合治疗较单用EVL减少再出血并降低死亡。

要点

  • Child A患者中,EVL+BB较单用BB减少总体再出血,发生率比0.40(95%CI 0.18-0.89;P=0.025),死亡无差异。
  • Child B/C患者中,EVL+BB较单用EVL减少再出血,并显著降低死亡,发生率比0.46(95%CI 0.25-0.85;P=0.013)。
  • EVL对再出血的效应按Child分级不同,交互作用P<0.001;BB是联合治疗的关键要素。

核心结论

  • 肝硬化严重程度影响静脉曲张再出血预防治疗的结局:Child A患者推荐联合治疗以更有效预防再出血但不改变生存,Child B/C患者单用EVL较联合治疗再出血和死亡风险增加,BB是联合治疗的关键要素。

研究设计与样本

  • 个体时间-事件患者数据荟萃分析,纳入比较EVL+BB与BB的3项随机对照试验共389例患者,以及比较EVL+BB与EVL的4项随机对照试验共416例患者。
  • 按肝硬化严重程度(Child A vs B/C)分层比较EVL+BB与单药治疗对全因再出血和死亡率的影响。

主要发现

  • 与单用BB相比,EVL+BB在Child A中减少总体再出血(发生率比0.40;95%CI 0.18-0.89;P=0.025),在Child B/C中未见减少,死亡率无差异。
  • EVL对再出血的效应按Child分级不同(交互作用P<0.001)。
  • 与单用EVL相比,EVL+BB在Child A和B/C中均减少再出血,并在Child B/C中显著降低死亡率(发生率比0.46;95%CI 0.25-0.85;P=0.013)。

关键数值与推荐

  • Child A患者中,EVL+BB较单用BB减少总体再出血,发生率比0.40(95%CI 0.18-0.89;P=0.025),死亡率无差异。
  • Child B/C患者中,EVL+BB较单用EVL减少再出血,并显著降低死亡率,发生率比0.46(95%CI 0.25-0.85;P=0.013)。
  • EVL对再出血的效应按Child分级不同,交互作用P<0.001。

临床怎么用

  • Child A患者推荐联合治疗以更有效预防再出血,但不改变生存。
  • Child B/C患者单用EVL较联合治疗再出血和死亡风险增加,BB是联合治疗的关键要素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Endoscopic variceal ligation plus beta-blockers (EVL+BB) is currently recommended for variceal rebleeding prophylaxis, a recommendation that extends to all patients with cirrhosis with previous variceal bleeding irrespective of prognostic stage. Individualizing patient care is relevant, and in published studies on variceal rebleeding prophylaxis, there is a lack of information regarding response to therapy by prognostic stage. This study aimed at comparing EVL plus BB with monotherapy (EVL or BB) on all-source rebleeding and mortality in patients with cirrhosis and previous variceal bleeding stratified by cirrhosis severity (Child A versus B/C) by means of individual time-to-event patient data meta-analysis from randomized controlled trials. The study used individual data on 389 patients from three trials comparing EVL plus BB versus BB and 416 patients from four trials comparing EVL plus BB versus EVL. Compared with BB alone, EVL plus BB reduced overall rebleeding in Child A (incidence rate ratio 0.40; 95% confidence interval, 0.18-0.89; P = 0.025) but not in Child B/C, without differences in mortality. The effect of EVL on rebleeding was different according to Child (P for interaction <0.001). Conversely, compared with EVL, EVL plus BB reduced rebleeding in both Child A and B/C, with a significant reduction in mortality in Child B/C (incidence rate ratio 0.46; 95% confidence interval, 0.25-0.85; P = 0.013). CONCLUSION: Outcomes of therapies to prevent variceal rebleeding differ depending on cirrhosis severity: in patients with preserved liver function (Child A), combination therapy is recommended because it is more effective in preventing rebleeding, without modifying survival, while in patients with advanced liver failure (Child B/C), EVL alone carries an increased risk of rebleeding and death compared with combination therapy, underlining that BB is the key element of combination therapy. (Hepatology 2017;66:1219-1231).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Albillos A, Zamora J, Martínez J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis. Hepatology. 2017. PMID: 28543862. doi:10.1002/hep.29267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。